These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26513003)

  • 1. Reducing the Risk of OHSS by GnRH Agonist Triggering.
    Casper RF
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4396-8. PubMed ID: 26513003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
    Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice.
    Chuderland D; Ben-Ami I; Kaplan-Kraicer R; Grossman H; Ron-El R; Shalgi R
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E258-66. PubMed ID: 23295464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger.
    Fatemi HM; Garcia-Velasco J
    Fertil Steril; 2015 Apr; 103(4):870-3. PubMed ID: 25724740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dual Role of PEDF in the Pathogenesis of OHSS: Negating Both Angiogenic and Inflammatory Pathways.
    Miller I; Chuderland D; Grossman H; Ron-El R; Ben-Ami I; Shalgi R
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4699-4709. PubMed ID: 27680872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone agonist (GnRHa) trigger - State of the art.
    Dosouto C; Haahr T; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):1-8. PubMed ID: 28215488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.
    Wang TH; Horng SG; Chang CL; Wu HM; Tsai YJ; Wang HS; Soong YK
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3300-8. PubMed ID: 12107240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
    Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
    Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction: Gonadotropin-releasing hormone agonist triggering of final follicular maturation for in vitro fertilization.
    Casper RF
    Fertil Steril; 2015 Apr; 103(4):865-6. PubMed ID: 25681856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic understanding of gonadotropin-releasing hormone-agonist triggering.
    Casper RF
    Fertil Steril; 2015 Apr; 103(4):867-9. PubMed ID: 25712575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of kisspeptin-54 on ovarian levels of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in an experimental model of ovarian hyperstimulation syndrome (OHSS).
    Birinci H; Vatansever HS; Yüncü M
    Reprod Fertil Dev; 2021 Nov; 33(16):799-809. PubMed ID: 34610858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The VEGF and PEDF levels in the follicular fluid of patients co- treated with LETROZOLE and gonadotropins during the stimulation cycle.
    Haas J; Bassil R; Gonen N; Meriano J; Jurisicova A; Casper RF
    Reprod Biol Endocrinol; 2018 May; 16(1):54. PubMed ID: 29843716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.